Abstract
The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to antiangiogenic therapy.
Keywords: Angiogenesis, angiogenesis inhibitors, bevacizumab, CNS neoplasm
Current Molecular Pharmacology
Title:Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Volume: 5
Author(s): Irina Veytsman, Jeanny B. Aragon-Ching and Sandra M. Swain
Affiliation:
Keywords: Angiogenesis, angiogenesis inhibitors, bevacizumab, CNS neoplasm
Abstract: The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to antiangiogenic therapy.
Export Options
About this article
Cite this article as:
Veytsman Irina, B. Aragon-Ching Jeanny and M. Swain Sandra, Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030007
DOI https://dx.doi.org/10.2174/1874467211205030007 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets FOXO1: A Potential Target for Human Diseases
Current Drug Targets Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Computational Studies on Translocator Protein (TSPO) and its Ligands
Current Topics in Medicinal Chemistry Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Current Pharmaceutical Design Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Patent Selections:
Current Biomarkers (Discontinued) Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Current Pharmaceutical Design ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets